{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T08:00:00Z","timestamp":1789286400024,"version":"build-2803163510"},"reference-count":160,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.dld.2026.02.001","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T20:37:38Z","timestamp":1771274258000},"page":"444-455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Adequacy criteria and reporting for prognostic and predictive profiling of biopsies from gastrointestinal neoplasia: A position paper from the Italian group of gastrointestinal pathologists, section of Italian society of anatomic pathology and cytology (GIPAD-SIAPeC-IAP)"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0591-6723","authenticated-orcid":false,"given":"Paola","family":"Parente","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6477-3182","authenticated-orcid":false,"given":"Federica","family":"Grillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde","family":"Callegarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4901-4908","authenticated-orcid":false,"given":"Claudio","family":"Luchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Milione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5601-0879","authenticated-orcid":false,"given":"Paola","family":"Mattiolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3271-2198","authenticated-orcid":false,"given":"Roberta","family":"Gaf\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Pagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Malapelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Macciomei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7389-3071","authenticated-orcid":false,"given":"Maria","family":"D\u2019Armiento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Raffaella","family":"Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1145-6025","authenticated-orcid":false,"given":"Francesco","family":"Vasuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Fanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Ingravallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8425-9658","authenticated-orcid":false,"given":"Francesco Giuseppe","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Pilozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Falco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5139-3869","authenticated-orcid":false,"given":"Alessandro","family":"Caputo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Panarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Pruneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Cassoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7826-002X","authenticated-orcid":false,"given":"Alessandro","family":"Gambella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9068-2225","authenticated-orcid":false,"given":"Luca","family":"Savino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Angerilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2976-7032","authenticated-orcid":false,"given":"Alessandro","family":"Vanoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0193-5281","authenticated-orcid":false,"given":"Luca","family":"Mastracci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6515-5482","authenticated-orcid":false,"given":"Matteo","family":"Fassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.dld.2026.02.001_bib0001","doi-asserted-by":"crossref","first-page":"248","DOI":"10.32074\/1591-951X-158","article-title":"Current prognostic and predictive biomarkers for gastrointestinal tumors in clinical practice","volume":"112","author":"Fassan","year":"2020","journal-title":"Pathologica"},{"issue":"3","key":"10.1016\/j.dld.2026.02.001_bib0002","doi-asserted-by":"crossref","first-page":"313","DOI":"10.5858\/arpa.2017-0269-RA","article-title":"Molecular diagnostics in pathology: time for a next-generation pathologist?","volume":"142","author":"Fassan","year":"2018","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"10.1016\/j.dld.2026.02.001_bib0003","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3390\/diagnostics11020339","article-title":"The role of the pathologist in the next-generation era of tumor molecular characterization","volume":"11","author":"Angerilli","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"21","key":"10.1016\/j.dld.2026.02.001_bib0004","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.dld.2026.02.001_bib0005","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.annonc.2025.05.528","article-title":"Localised rectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Hofheinz","year":"2025","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.dld.2026.02.001_bib0006","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1080\/14737159.2023.2288267","article-title":"A charming molecular profile in the wrong tissue: the pathologist in the era of molecular diagnostics in the gastrointestinal tract","volume":"23","author":"Parente","year":"2023","journal-title":"Expert Rev Mol Diagn"},{"issue":"8","key":"10.1016\/j.dld.2026.02.001_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103647","article-title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer","volume":"9","author":"Chen","year":"2024","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.dld.2026.02.001_bib0008","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.dld.2026.02.001_bib0009","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.dld.2026.02.001_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102226","article-title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer","volume":"9","author":"Shitara","year":"2024","journal-title":"ESMO Open"},{"issue":"11","key":"10.1016\/j.dld.2026.02.001_bib0011","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.dld.2026.02.001_bib0012","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.dld.2026.02.001_bib0013","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.5858\/arpa.2019-0009-SA","article-title":"Preanalytics and precision pathology: pathology practices to ensure molecular integrity of cancer patient biospecimens for precision medicine","volume":"143","author":"Compton","year":"2019","journal-title":"Arch Pathol Lab Med"},{"issue":"Pt 2","key":"10.1016\/j.dld.2026.02.001_bib0014","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.semcancer.2017.12.008","article-title":"Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy","volume":"52","author":"Agrawal","year":"2018","journal-title":"Semin Cancer Biol"},{"issue":"9","key":"10.1016\/j.dld.2026.02.001_bib0015","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/PAI.0000000000001153","article-title":"Impact of prolonged ischemia on the immunohistochemical expression of programmed death ligand 1 (PD-L1)","volume":"31","author":"Barber\u00e0","year":"2023","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"8","key":"10.1016\/j.dld.2026.02.001_bib0016","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1038\/modpathol.2012.59","article-title":"The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma","volume":"25","author":"Yildiz-Aktas","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.dld.2026.02.001_bib0017","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.nbt.2019.05.007","article-title":"Tissues under-vacuum to overcome suboptimal preservation","volume":"52","author":"Annaratone","year":"2019","journal-title":"N Biotechnol"},{"issue":"11","key":"10.1016\/j.dld.2026.02.001_bib0018","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.5858\/arpa.2013-0691-RA","article-title":"A review of preanalytical factors affecting molecular, protein, and morphological analysis of formalin-fixed, paraffin-embedded (FFPE) tissue: how well do you know your FFPE specimen?","volume":"138","author":"Bass","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.dld.2026.02.001_bib0019","series-title":"Molecular histopathology and tissue biomarkers in drug and diagnostic development","first-page":"259","article-title":"The impact of pre-analytic variables on tissue quality from clinical samples collected in a routine clinical setting: implications for diagnostic evaluation, drug discovery, and translational research. In:","author":"Hicks","year":"2015"},{"issue":"5","key":"10.1016\/j.dld.2026.02.001_bib0020","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00428-023-03661-z","article-title":"Impact of formalin fixation on mismatch repair protein evaluation by immunohistochemistry","volume":"483","author":"Grillo","year":"2023","journal-title":"Virchows Arch"},{"key":"10.1016\/j.dld.2026.02.001_bib0021","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.32074\/1591-951X-1215","article-title":"Part I - pre-analytical phase","volume":"117","author":"Marchi\u00f2","year":"2025","journal-title":"Pathologica"},{"issue":"6","key":"10.1016\/j.dld.2026.02.001_bib0022","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00418-024-02326-5","article-title":"Be bold, start cold! cold formalin fixation of colorectal cancer specimens granted superior DNA and RNA quality for downstream molecular analysis","volume":"162","author":"Nano","year":"2024","journal-title":"Histochem Cell Biol"},{"issue":"6","key":"10.1016\/j.dld.2026.02.001_bib0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021043","article-title":"Formalin fixation at low temperature better preserves nucleic acid integrity","volume":"6","author":"Bussolati","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.dld.2026.02.001_bib0024","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1373\/clinchem.2014.223040","article-title":"Sequence artifacts in DNA from formalin-fixed tissues: causes and strategies for minimization","volume":"61","author":"Do","year":"2015","journal-title":"Clin Chem"},{"issue":"1\u20132","key":"10.1016\/j.dld.2026.02.001_bib0025","first-page":"77","article-title":"DNA damage caused by common cytological fixatives","volume":"401","author":"Douglas","year":"1998","journal-title":"Mutat Res"},{"issue":"9","key":"10.1016\/j.dld.2026.02.001_bib0026","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.3390\/ijms17091579","article-title":"Pre-analytical considerations for successful next-generation sequencing (NGS): challenges and opportunities for formalin-fixed and paraffin-embedded tumor tissue (FFPE) samples","volume":"17","author":"Arreaza","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.dld.2026.02.001_bib0027","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.5858\/132.12.1929","article-title":"Tissue handling and specimen preparation in surgical pathology: issues concerning the recovery of nucleic acids from formalin-fixed, paraffin-embedded tissue","volume":"132","author":"Hewitt","year":"2008","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.dld.2026.02.001_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-319-13957-9_1","article-title":"The pre-analytical phase in surgical pathology","volume":"199","author":"Bussolati","year":"2015","journal-title":"Recent Results Cancer Res"},{"issue":"11","key":"10.1016\/j.dld.2026.02.001_bib0029","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/jclinpath-2017-204387","article-title":"Immunohistochemistry on old archival paraffin blocks: is there an expiry date?","volume":"70","author":"Grillo","year":"2017","journal-title":"J Clin Pathol"},{"issue":"1","key":"10.1016\/j.dld.2026.02.001_bib0030","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00418-015-1316-4","article-title":"Factors affecting immunoreactivity in long-term storage of formalin-fixed paraffin-embedded tissue sections","volume":"144","author":"Grillo","year":"2015","journal-title":"Histochem Cell Biol"},{"issue":"1","key":"10.1016\/j.dld.2026.02.001_bib0031","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13000-023-01423-8","article-title":"Effect of storage time of paraffin sections on the expression of PD-L1 (SP142) in invasive breast cancer","volume":"18","author":"He","year":"2023","journal-title":"Diagn Pathol"},{"issue":"19","key":"10.1016\/j.dld.2026.02.001_bib0032","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.3390\/cancers17193103","article-title":"Decline of PD-L1 immunoreactivity with storage duration in Formalin-fixed paraffin-embedded breast cancer specimens: implications for diagnostic accuracy and immunotherapy eligibility in triple-negative breast can","volume":"17","author":"Yanagihara","year":"2025","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.dld.2026.02.001_bib0033","doi-asserted-by":"crossref","first-page":"57","DOI":"10.32074\/1591-951X-836","article-title":"A practical approach for PD-L1 evaluation in gastroesophageal cancer","volume":"115","author":"Angerilli","year":"2023","journal-title":"Pathologica"},{"issue":"4","key":"10.1016\/j.dld.2026.02.001_bib0034","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/s41379-019-0372-z","article-title":"Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies","volume":"33","author":"Lawson","year":"2020","journal-title":"Mod Pathol"},{"issue":"9","key":"10.1016\/j.dld.2026.02.001_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100220","article-title":"Impact of decalcification, cold ischemia, and deglycosylation on performance of programmed cell death ligand-1 antibodies with different binding epitopes: comparison of 7 clones","volume":"36","author":"Lawson","year":"2023","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.dld.2026.02.001_bib0036","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.pathol.2020.10.015","article-title":"Comparison of PD-L1 immunohistochemical assays in advanced gastric adenocarcinomas using endoscopic biopsy and paired resected specimens","volume":"53","author":"Kim","year":"2021","journal-title":"Pathology"},{"issue":"4","key":"10.1016\/j.dld.2026.02.001_bib0037","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s10120-022-01301-0","article-title":"Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy","volume":"25","author":"Yeong","year":"2022","journal-title":"Gastric Cancer"},{"issue":"11","key":"10.1016\/j.dld.2026.02.001_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100589","article-title":"Claudin-18.2 immunohistochemical evaluation in gastric and gastroesophageal junction adenocarcinomas to direct targeted therapy: a practical approach","volume":"37","author":"Fassan","year":"2024","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.dld.2026.02.001_bib0039","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1593\/tlo.12334","article-title":"The reliability of endoscopic biopsies in assessing HER2 status in gastric and gastroesophageal junction cancer: a study comparing biopsies with surgical samples","volume":"6","author":"Grillo","year":"2013","journal-title":"Transl Oncol"},{"key":"10.1016\/j.dld.2026.02.001_bib0040","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.humpath.2015.08.023","article-title":"Heterogeneous Her2\/neu expression in gastric and gastroesophageal cancer","volume":"48","author":"Grillo","year":"2016","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1016\/j.dld.2026.02.001_bib0041","doi-asserted-by":"crossref","first-page":"E165","DOI":"10.1055\/s-0034-1391359","article-title":"Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer","volume":"3","author":"Gullo","year":"2015","journal-title":"Endosc Int Open"},{"issue":"2","key":"10.1016\/j.dld.2026.02.001_bib0042","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s13304-022-01330-5","article-title":"Current molecular biomarkers evaluation in gastric\/gastroesophageal junction adenocarcinoma: pathologist does matter","volume":"75","author":"Businello","year":"2023","journal-title":"Updates Surg"},{"issue":"11","key":"10.1016\/j.dld.2026.02.001_bib0043","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3390\/jpm11111095","article-title":"Association of CLDN18 protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction adenocarcinomas","volume":"11","author":"Pellino","year":"2021","journal-title":"JPM"},{"issue":"2","key":"10.1016\/j.dld.2026.02.001_bib0044","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.dld.2025.12.005","article-title":"Number\/quality of endoscopic biopsy samples in gastrointestinal cancers for biomarker testing: All that glitters is not gold","volume":"58","author":"Grillo","year":"2026","journal-title":"Dig Liver Dis"},{"issue":"2","key":"10.1016\/j.dld.2026.02.001_bib0045","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00418-023-02202-8","article-title":"Evaluating mismatch repair deficiency in colorectal cancer biopsy specimens","volume":"160","author":"Grillo","year":"2023","journal-title":"Histochem Cell Biol"},{"issue":"9","key":"10.1016\/j.dld.2026.02.001_bib0046","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.dld.2025.05.026","article-title":"The current success of precision oncology relies on precision diagnostics: how quality and quantity of endoscopic biopsies impact cancer patient outcome","volume":"57","author":"Fassan","year":"2025","journal-title":"Dig Liver Dis"},{"issue":"4","key":"10.1016\/j.dld.2026.02.001_bib0047","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","article-title":"HER2 Testing and Clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology","volume":"35","author":"Bartley","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.dld.2026.02.001_bib0048","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.humpath.2008.11.014","article-title":"HER-2 amplification is highly homogenous in gastric cancer","volume":"40","author":"Marx","year":"2009","journal-title":"Hum Pathol"},{"issue":"9","key":"10.1016\/j.dld.2026.02.001_bib0049","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1038\/bjc.2011.121","article-title":"Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma","volume":"104","author":"Bozzetti","year":"2011","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.dld.2026.02.001_bib0050","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/j.1365-2559.2011.04012.x","article-title":"Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma","volume":"59","author":"Kim","year":"2011","journal-title":"Histopathology"},{"issue":"8","key":"10.1016\/j.dld.2026.02.001_bib0051","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.humpath.2011.09.004","article-title":"Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas","volume":"43","author":"Fassan","year":"2012","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1016\/j.dld.2026.02.001_bib0052","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3748\/wjg.v18.i2.150","article-title":"Human epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology","volume":"18","author":"Tsapralis","year":"2012","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.dld.2026.02.001_bib0053","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/modpathol.2012.228","article-title":"HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions","volume":"26","author":"Fusco","year":"2013","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.dld.2026.02.001_bib0054","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/modpathol.2012.205","article-title":"Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas","volume":"26","author":"Cho","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.dld.2026.02.001_bib0055","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/1746-1596-8-191","article-title":"Differing deregulation of HER2 in primary gastric cancer and synchronous related metastatic lymph nodes","volume":"8","author":"Kochi","year":"2013","journal-title":"Diagn Pathol"},{"issue":"24","key":"10.1016\/j.dld.2026.02.001_bib0056","doi-asserted-by":"crossref","first-page":"10607","DOI":"10.7314\/APJCP.2014.15.24.10607","article-title":"Is her-2 status in the primary tumor correlated with matched lymph node metastases in patients with gastric cancer undergoing curative gastrectomy?","volume":"15","author":"Selcukbiricik","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.dld.2026.02.001_bib0057","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/234851","article-title":"HER2 Status in premalignant, early, and advanced neoplastic lesions of the stomach","volume":"2015","author":"Ieni","year":"2015","journal-title":"Dis Markers"},{"issue":"12","key":"10.1016\/j.dld.2026.02.001_bib0058","doi-asserted-by":"crossref","first-page":"22331","DOI":"10.3390\/ijms151222331","article-title":"Discordance rate of HER2 status in primary gastric carcinomas and synchronous lymph node metastases: a multicenter retrospective analysis","volume":"15","author":"Ieni","year":"2014","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.dld.2026.02.001_bib0059","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/jjco\/hyv020","article-title":"Discordances in HER2 status between primary gastric cancer and corresponding metastatic sites","volume":"45","author":"Gumusay","year":"2015","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"10.1016\/j.dld.2026.02.001_bib0060","first-page":"163","article-title":"HER2 discordance between paired primary gastric cancer and metastasis: a meta-analysis","volume":"27","author":"Peng","year":"2015","journal-title":"Chin J Cancer Res"},{"issue":"1","key":"10.1016\/j.dld.2026.02.001_bib0061","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1038\/s41598-017-03304-9","article-title":"Discordance in HER2 status in gastro-esophageal adenocarcinomas: a systematic review and meta-analysis","volume":"7","author":"Creemers","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.dld.2026.02.001_bib0062","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s12253-016-0082-5","article-title":"HER2 Status in gastric cancer: comparison between primary and distant metastatic disease","volume":"23","author":"Amato","year":"2017","journal-title":"Pathol Oncol Res"},{"issue":"4","key":"10.1016\/j.dld.2026.02.001_bib0063","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s10120-025-01609-7","article-title":"Heterogeneity of predictive biomarker expression in gastric and esophago-gastric junction carcinoma with peritoneal dissemination","volume":"28","author":"Angerilli","year":"2025","journal-title":"Gastric Cancer"},{"issue":"1","key":"10.1016\/j.dld.2026.02.001_bib0064","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s40880-017-0226-3","article-title":"Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma","volume":"36","author":"Gao","year":"2017","journal-title":"Chin J Cancer"},{"key":"10.1016\/j.dld.2026.02.001_bib0065","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3389\/fonc.2019.00136","article-title":"Expression of PD-L1 and PD-1 in chemoradiotherapy-na\u00efve esophageal and gastric adenocarcinoma: relationship with mismatch repair status and survival","volume":"9","author":"Svensson","year":"2019","journal-title":"Front Oncol"},{"issue":"14","key":"10.1016\/j.dld.2026.02.001_bib0066","doi-asserted-by":"crossref","first-page":"13345","DOI":"10.1007\/s00432-023-05142-x","article-title":"Programmed death-ligand 1 (PD-L1) expression in primary gastric adenocarcinoma and matched metastases","volume":"149","author":"Liu","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"10.1016\/j.dld.2026.02.001_bib0067","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41416-019-0508-4","article-title":"Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases","volume":"121","author":"Coati","year":"2019","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.dld.2026.02.001_bib0068","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1158\/2159-8290.CD-17-0395","article-title":"Genomic heterogeneity as a barrier to precision medicine in gastroesophageal adenocarcinoma","volume":"8","author":"Pectasides","year":"2018","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.dld.2026.02.001_bib0069","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41575-022-00703-w","article-title":"Current developments in gastric cancer: from molecular profiling to treatment strategy","volume":"20","author":"Alsina","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.dld.2026.02.001_bib0070","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1186\/s13059-014-0454-7","article-title":"Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions","volume":"15","author":"Brannon","year":"2014","journal-title":"Genome Biol"},{"key":"10.1016\/j.dld.2026.02.001_bib0071","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ebiom.2019.01.050","article-title":"Biomarker concordance between primary colorectal cancer and its metastases","volume":"40","author":"Bhullar","year":"2019","journal-title":"EBioMedicine"},{"issue":"7","key":"10.1016\/j.dld.2026.02.001_bib0072","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/jclinpath-2022-208143","article-title":"MMR profile and microsatellite instability status in colorectal mucinous adenocarcinoma with synchronous metastasis: a new clue for the clinical practice","volume":"76","author":"Parente","year":"2023","journal-title":"J Clin Pathol"},{"issue":"3","key":"10.1016\/j.dld.2026.02.001_bib0073","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00428-022-03343-2","article-title":"Expert opinion on NSCLC small specimen biomarker testing - part 1: tissue collection and management","volume":"481","author":"Penault-Llorca","year":"2022","journal-title":"Virchows Arch"},{"issue":"10","key":"10.1016\/j.dld.2026.02.001_bib0074","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1016\/j.humpath.2014.07.005","article-title":"How reliable is immunohistochemical staining for DNA mismatch repair proteins performed after neoadjuvant chemoradiation?","volume":"45","author":"Vilkin","year":"2014","journal-title":"Hum Pathol"},{"issue":"5","key":"10.1016\/j.dld.2026.02.001_bib0075","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1159\/000531003","article-title":"The day-to-day practice of MMR and MSI assessment in colorectal adenocarcinoma: what we know and what we still need to explore","volume":"41","author":"Parente","year":"2023","journal-title":"Dig Dis"},{"issue":"12","key":"10.1016\/j.dld.2026.02.001_bib0076","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1097\/PAS.0b013e3181f906cc","article-title":"Neoadjuvant therapy induces loss of MSH6 expression in colorectal carcinoma","volume":"34","author":"Bao","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.dld.2026.02.001_bib0077","doi-asserted-by":"crossref","first-page":"166","DOI":"10.32074\/1591-951X-166","article-title":"Precancerous lesions of the stomach, gastric cancer and hereditary gastric cancer syndromes","volume":"112","author":"Gullo","year":"2020","journal-title":"Pathologica"},{"issue":"3","key":"10.1016\/j.dld.2026.02.001_bib0078","doi-asserted-by":"crossref","first-page":"138","DOI":"10.32074\/1591-951X-164","article-title":"Neoplastic and pre-neoplastic lesions of the oesophagus and gastro-oesophageal junction","volume":"112","author":"Grillo","year":"2020","journal-title":"Pathologica"},{"issue":"5","key":"10.1016\/j.dld.2026.02.001_bib0079","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1365-2559.2012.04272.x","article-title":"Early HER2 dysregulation in gastric and oesophageal carcinogenesis","volume":"61","author":"Fassan","year":"2012","journal-title":"Histopathology"},{"issue":"5","key":"10.1016\/j.dld.2026.02.001_bib0080","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/j.1365-2559.2011.04017.x","article-title":"Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections","volume":"59","author":"Lee","year":"2011","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.dld.2026.02.001_bib0081","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00428-019-02693-8","article-title":"PD-L1 expression in gastroesophageal dysplastic lesions","volume":"477","author":"Fassan","year":"2020","journal-title":"Virchows Arch"},{"issue":"7","key":"10.1016\/j.dld.2026.02.001_bib0082","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/his.14647","article-title":"Mismatch repair status and gastro-oesophageal dysplasia: need for a dedicated gastrointestinal pathologist?","volume":"80","author":"Angerilli","year":"2022","journal-title":"Histopathology"},{"issue":"4","key":"10.1016\/j.dld.2026.02.001_bib0083","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00428-022-03392-7","article-title":"Molecular subtyping of gastroesophageal dysplasia heterogeneity according to TCGA\/ACRG classes","volume":"481","author":"Angerilli","year":"2022","journal-title":"Virchows Arch"},{"issue":"6","key":"10.1016\/j.dld.2026.02.001_bib0084","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s10120-023-01411-3","article-title":"Concordance of microsatellite instability and mismatch repair status in paired biopsies and surgical specimens of resectable gastroesophageal adenocarcinoma: time for a call to action","volume":"26","author":"Fornaro","year":"2023","journal-title":"Gastric Cancer"},{"issue":"3","key":"10.1016\/j.dld.2026.02.001_bib0085","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.3390\/cancers7030859","article-title":"Analysis of pre-analytic factors affecting the success of clinical next-generation sequencing of solid organ malignancies","volume":"7","author":"Chen","year":"2015","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.dld.2026.02.001_bib0086","first-page":"137","article-title":"The ideal reporting of RAS testing in colorectal adenocarcinoma: a pathologists\u2019 perspective","volume":"115","author":"Malapelle","year":"2023","journal-title":"Pathologica"},{"key":"10.1016\/j.dld.2026.02.001_bib0087","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/1471-2164-6-142","article-title":"Macrodissection versus microdissection of rectal carcinoma: minor influence of stroma cells to tumor cell gene expression profiles","volume":"6","author":"de Bruin","year":"2005","journal-title":"BMC Genom"},{"issue":"9","key":"10.1016\/j.dld.2026.02.001_bib0088","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.3390\/cells9092019","article-title":"Impact of pre-analytical factors on MSI test accuracy in mucinous colorectal adenocarcinoma: a multi-assay concordance study","volume":"9","author":"Malapelle","year":"2020","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.dld.2026.02.001_bib0089","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jasc.2022.11.003","article-title":"Cell blocks in cytology: review of preparation methods, advantages, and limitations","volume":"12","author":"Torous","year":"2023","journal-title":"J Am Soc Cytopathol"},{"issue":"6","key":"10.1016\/j.dld.2026.02.001_bib0090","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/cncy.22688","article-title":"Claudin18.2 expression and clinicopathological features in cytology effusion specimens from gastric adenocarcinoma: a comparative study with tissue specimens","volume":"131","author":"Dai","year":"2023","journal-title":"Cancer Cytopathol"},{"issue":"1","key":"10.1016\/j.dld.2026.02.001_bib0091","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5858\/arpa.2019-0398-OA","article-title":"Evaluating mismatch repair\/microsatellite instability status using cytology effusion specimens to determine eligibility for immunotherapy","volume":"145","author":"Jacobi","year":"2021","journal-title":"Arch Pathol Lab Med"},{"issue":"11","key":"10.1016\/j.dld.2026.02.001_bib0092","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.5858\/arpa.2016-0108-RA","article-title":"Optimizing workflows and processing of cytologic samples for comprehensive analysis by next-generation sequencing: memorial Sloan Kettering Cancer Center experience","volume":"140","author":"Tian","year":"2016","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"10.1016\/j.dld.2026.02.001_bib0093","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1159\/000495661","article-title":"Diff-quik cytology smears from endobronchial ultrasound transbronchial needle aspiration lymph node specimens as a source of DNA for next-generation sequencing instead of cell blocks","volume":"97","author":"Fielding","year":"2019","journal-title":"Respiration"},{"issue":"2","key":"10.1016\/j.dld.2026.02.001_bib0094","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104134","article-title":"ESMO Clinical Practice Guideline interim update on the treatment of locally advanced oesophageal and oesophagogastric junction adenocarcinoma and metastatic squamous-cell carcinoma","volume":"10","author":"Obermannov\u00e1","year":"2025","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.dld.2026.02.001_bib0095","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","article-title":"Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Obermannov\u00e1","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2026.02.001_bib0096","first-page":"352","article-title":"PD-L1 evaluation in the gastrointestinal tract: from biological rationale to its clinical application","volume":"114","author":"Mastracci","year":"2022","journal-title":"Pathol - J Ital Soc Anat Pathol Diagn Cytopathol"},{"issue":"5","key":"10.1016\/j.dld.2026.02.001_bib0097","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N Engl J Med"},{"issue":"10302","key":"10.1016\/j.dld.2026.02.001_bib0098","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2026.02.001_bib0099","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1200\/JCO.20.01888","article-title":"KEYNOTE-181 Investigators. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer","volume":"10","author":"Kojima","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.dld.2026.02.001_bib0100","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13000-023-01318-8","article-title":"Tumor Area Positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring","volume":"18","author":"Liu","year":"2023","journal-title":"Diagn Pathol"},{"issue":"3","key":"10.1016\/j.dld.2026.02.001_bib0101","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41416-019-0515-5","article-title":"Can PD-L1 expression evaluated by biopsy sample accurately reflect its expression in the whole tumour in gastric cancer?","volume":"121","author":"Yamashita","year":"2019","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.dld.2026.02.001_bib0102","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105846","article-title":"Critical insights on real-life PD-L1 histopathological workflow and assessment in esophageal, esophagogastric junction, and gastric carcinoma in Italy","volume":"10","author":"Gambella","year":"2025","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.dld.2026.02.001_bib0103","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"et al.; ESMO Guidelines Committee. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2026.02.001_bib0104","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102971","article-title":"FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma","volume":"139","author":"Smyth","year":"2025","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.dld.2026.02.001_bib0105","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/modpathol.2011.198","article-title":"HER2 testing in gastric cancer: a practical approach","volume":"25","author":"R\u00fcschoff","year":"2012","journal-title":"Mod Pathol"},{"issue":"7","key":"10.1016\/j.dld.2026.02.001_bib0106","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","article-title":"Assessment of a HER2 scoring system for gastric cancer: results from a validation study","volume":"52","author":"Hofmann","year":"2008","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.dld.2026.02.001_bib0107","doi-asserted-by":"crossref","first-page":"330","DOI":"10.5858\/arpa.2018-0043-OA","article-title":"Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of Pembrolizumab for treatment of gastric cancer","volume":"143","author":"Kulangara","year":"2019","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"10.1016\/j.dld.2026.02.001_bib0108","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2023.100128","article-title":"Multi-institutional study of pathologist reading of the programmed cell death ligand-1 combined positive score immunohistochemistry assay for gastric or gastroesophageal junction cancer","volume":"36","author":"Fernandez","year":"2023","journal-title":"Mod Pathol"},{"issue":"9","key":"10.1016\/j.dld.2026.02.001_bib0109","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2025.100793","article-title":"Concordance between the PD-L1 tumor area positivity score and combined positive score for gastric or esophageal cancers treated with Tislelizumab","volume":"38","author":"Moehler","year":"2025","journal-title":"Mod Pathol"},{"key":"10.1016\/j.dld.2026.02.001_bib0110","article-title":"PD-L1 immunohistochemistry in gastric cancer: comparison of combined positive score and tumor area positivity across 28-8, 22C3, and SP263 assays","volume":"8","author":"Klempner","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.dld.2026.02.001_bib0111","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12935-020-01273-0","article-title":"Heterogeneous programmed death-ligand 1 expression in gastric cancer: comparison of tissue microarrays and whole sections","volume":"20","author":"Ye","year":"2020","journal-title":"Cancer Cell Int"},{"issue":"8","key":"10.1016\/j.dld.2026.02.001_bib0112","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1093\/annonc\/mdz116","article-title":"ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1\/PD-L1 expression and tumour mutational burden: a systematic review-based approach","volume":"30","author":"Luchini","year":"2019","journal-title":"Annals of Oncology"},{"issue":"7517","key":"10.1016\/j.dld.2026.02.001_bib0113","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","author":"The Cancer","year":"2014","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.dld.2026.02.001_bib0114","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2020.100036","article-title":"Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials","volume":"6","author":"Pietrantonio","year":"2021","journal-title":"ESMO Open"},{"issue":"12","key":"10.1016\/j.dld.2026.02.001_bib0115","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/s41379-022-01149-w","article-title":"Validity of a two-antibody testing algorithm for mismatch repair deficiency testing in cancer; a systematic literature review and meta-analysis","volume":"35","author":"Aiyer","year":"2022","journal-title":"Mod Pathol"},{"key":"10.1016\/j.dld.2026.02.001_bib0116","article-title":"Prevalence of FGFR2b protein overexpression in advanced gastric cancers during prescreening for the phase III FORTITUDE-101 trial","volume":"9","author":"Rha","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.dld.2026.02.001_bib0117","doi-asserted-by":"crossref","first-page":"20","DOI":"10.7150\/jca.28204","article-title":"Pathological and prognostic impacts of FGFR2 overexpression in gastric cancer: a meta-analysis","volume":"10","author":"Kim","year":"2019","journal-title":"J Cancer"},{"issue":"9","key":"10.1016\/j.dld.2026.02.001_bib0118","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/modpathol.2016.96","article-title":"FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival","volume":"29","author":"Ahn","year":"2016","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.dld.2026.02.001_bib0119","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1093\/annonc\/mdx081","article-title":"Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?","volume":"28","author":"Hierro","year":"2017","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.dld.2026.02.001_bib0120","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s10120-024-01466-w","article-title":"Bemarituzumab as first-line treatment for locally advanced or metastatic gastric\/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial","volume":"27","author":"Wainberg","year":"2024","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.dld.2026.02.001_bib0121","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4164","article-title":"Trial in progress: phase 3 study of bemarituzumab + mFOLFOX6 versus placebo + mFOLFOX6 in previously untreated advanced gastric or gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-101)","volume":"40","author":"Smyth","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.dld.2026.02.001_bib0122","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1245\/s10434-011-2173-6","article-title":"A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease","volume":"19","author":"Overman","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.1016\/j.dld.2026.02.001_bib0123","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.6004\/jnccn.2019.7344","article-title":"Small bowel adenocarcinoma: etiology, presentation, and molecular alterations","volume":"17","author":"Pedersen","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"13","key":"10.1016\/j.dld.2026.02.001_bib0124","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1158\/1078-0432.CCR-21-0159","article-title":"ZEBRA: a multicenter Phase II study of Pembrolizumab in patients with advanced small-bowel adenocarcinoma","volume":"27","author":"Pedersen","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.dld.2026.02.001_bib0125","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1001\/jamaoncol.2017.1051","article-title":"Genomic profiling of small-bowel adenocarcinoma","volume":"3","author":"Schrock","year":"2017","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.dld.2026.02.001_bib0126","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2025.100825","article-title":"HER2, HER3, and mismatch repair protein expression in stage IV small bowel adenocarcinoma: results from a multicenter series","volume":"38","author":"Vanoli","year":"2025","journal-title":"Mod Pathol."},{"issue":"3","key":"10.1016\/j.dld.2026.02.001_bib0127","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100132","article-title":"Metastatic small bowel adenocarcinoma: role of metastasectomy and systemic chemotherapy","volume":"6","author":"Bhamidipati","year":"2021","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.dld.2026.02.001_bib0128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability\/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.dld.2026.02.001_bib0129","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.3390\/cancers16183145","article-title":"Prognostic and predictive roles of HER2 status in non-breast and non-gastroesophageal carcinomas","volume":"16","author":"Quaquarini","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.dld.2026.02.001_bib0130","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of Trastuzumab Deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 Phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.dld.2026.02.001_bib0131","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3892\/ol.2023.14197","article-title":"Successful treatment with trastuzumab plus chemotherapy as the first\u2011line regimen in advanced small bowel adenocarcinoma harboring HER2 amplification: a report of two cases","volume":"27","author":"Wang","year":"2024","journal-title":"Oncol Lett"},{"key":"10.1016\/j.dld.2026.02.001_bib0132","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in oncology (NCCN Guidelines\u00ae) for small bowel adenocarcinoma V.4.2025."},{"issue":"8","key":"10.1016\/j.dld.2026.02.001_bib0133","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.dld.2026.02.001_bib0134","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/annonc\/mdz233","article-title":"Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"30","author":"Stjepanovic","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.dld.2026.02.001_bib0135","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/CEJ.0000000000000677","article-title":"Universal testing for MSI\/MMR status in colorectal and endometrial cancers to identify Lynch syndrome cases: state of the art in Italy and consensus recommendations from the Italian Association for the Study of Familial Gastrointestinal Tumors (A.I.F.E.G.)","volume":"31","author":"Tibiletti","year":"2022","journal-title":"Eur J Cancer Prev"},{"key":"10.1016\/j.dld.2026.02.001_bib0136","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1200\/EDBK_208341","article-title":"Recent Advances in Lynch Syndrome: Diagnosis, Treatment, and Cancer Prevention","volume":"23","author":"Yurgelun","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"10","key":"10.1016\/j.dld.2026.02.001_bib0137","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.annonc.2020.06.022","article-title":"Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Argil\u00e9s","year":"2020","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.dld.2026.02.001_bib0138","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa2402141","article-title":"Nivolumab plus Ipilimumab in microsatellite-instability-high metastatic colorectal cancer","volume":"391","author":"Andre","year":"2024","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.dld.2026.02.001_bib0139","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.dld.2026.02.001_bib0140","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.22.01351","article-title":"Neoadjuvant pembrolizumab in localized microsatellite instability high\/deficient mismatch repair solid tumors","volume":"41","author":"Ludford","year":"2023","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.dld.2026.02.001_bib0141","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa2201445","article-title":"PD-1 blockade in mismatch repair\u2013Deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.dld.2026.02.001_bib0142","first-page":"219","article-title":"KRAS G12C metastatic colorectal cancer: specific features of a new emerging target population","volume":"19","author":"Schirripa","year":"2020","journal-title":"Clin Colorectal Cancer"},{"issue":"23","key":"10.1016\/j.dld.2026.02.001_bib0143","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","article-title":"Sotorasib plus Panitumumab in refractory colorectal cancer with mutated KRAS G12C","volume":"389","author":"Fakih","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.dld.2026.02.001_bib0144","first-page":"660","article-title":"BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies","volume":"6","author":"Clarke","year":"2015","journal-title":"J Gastrointest Oncol"},{"issue":"4","key":"10.1016\/j.dld.2026.02.001_bib0145","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/sj.bjc.6605177","article-title":"KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer","volume":"101","author":"Loupakis","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.dld.2026.02.001_bib0146","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103647","article-title":"BRAF-mutated colorectal adenocarcinomas: pathological heterogeneity and clinical implications","volume":"172","author":"Angerilli","year":"2022","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"5","key":"10.1016\/j.dld.2026.02.001_bib0147","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.ejca.2015.01.054","article-title":"Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis","volume":"51","author":"Pietrantonio","year":"2015","journal-title":"Eur J Cancer"},{"issue":"17","key":"10.1016\/j.dld.2026.02.001_bib0148","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.dld.2026.02.001_bib0149","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib plus Cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.dld.2026.02.001_bib0150","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa2501912","article-title":"Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-mutated colorectal cancer","volume":"392","author":"Elez","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.dld.2026.02.001_bib0151","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/his.15133","article-title":"BRAFV600E immunohistochemistry can reliably substitute BRAF molecular testing in the Lynch syndrome screening algorithm in colorectal cancer","volume":"84","author":"Grillo","year":"2024","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.dld.2026.02.001_bib0152","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/his.13315","article-title":"BRAF p.V600E-specific immunohistochemical assessment in colorectal cancer endoscopy biopsies is consistent with the mutational profiling","volume":"71","author":"Galuppini","year":"2017","journal-title":"Histopathology"},{"key":"10.1016\/j.dld.2026.02.001_bib0153","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104574","article-title":"Detecting BRAF mutations in colorectal cancer in clinical practice: an Italian experts\u2019 position paper","volume":"206","author":"Malapelle","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.dld.2026.02.001_bib0154","first-page":"1","article-title":"HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target","volume":"42","author":"Ahcene Djaballah","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"6","key":"10.1016\/j.dld.2026.02.001_bib0155","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(21)00086-3","article-title":"Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial","volume":"22","author":"Siena","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.dld.2026.02.001_bib0156","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1470-2045(23)00150-X","article-title":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study","volume":"24","author":"Strickler","year":"2023","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.dld.2026.02.001_bib0157","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/modpathol.2015.98","article-title":"Assessment of a HER2 scoring system for colorectal cancer: results from a validation study","volume":"28","author":"Valtorta","year":"2015","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.dld.2026.02.001_bib0158","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.dld.2026.02.001_bib0159","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100654","article-title":"Evidence for unified assessment criteria of HER2 immunohistochemistry in colorectal carcinoma","volume":"38","author":"Evans","year":"2025","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.dld.2026.02.001_bib0160","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1158\/2159-8290.CD-21-0521","article-title":"PD-1 blockade in solid tumors with defects in Polymerase Epsilon","volume":"12","author":"Rousseau","year":"2022","journal-title":"Cancer Discov"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865826002665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865826002665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T07:26:26Z","timestamp":1777620386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865826002665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":160,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1590865826002665"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2026.02.001","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adequacy criteria and reporting for prognostic and predictive profiling of biopsies from gastrointestinal neoplasia: A position paper from the Italian group of gastrointestinal pathologists, section of Italian society of anatomic pathology and cytology (GIPAD-SIAPeC-IAP)","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2026.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}